MarketScreener

Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therap…

Accelerated approval based on data demonstrating clinically meaningful efficacy, including a 42 percent overall response rate ...